Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>Supplementary Figure S5. The detailed effect of obinutuzumab pretreatment followed by CEA-IL2v on six timepoints from screening to Cycle 4 Day 5 of treatment. A, Peripheral blood natural killer cell count. B, Proliferating peripheral blood CD8+ T-cell count. C, Peripheral blood CD19+ B-cell count. C, cycle; CEA-IL2v, cergutuzumab amunaleukin; D, Day</p>

Original publication





Publication Date